18:56 , Aug 9, 2019 |  BC Extra  |  Clinical News

AZ notches another win in cancer with Tagrisso in NSCLC

AstraZeneca continued its momentum of positive cancer news this summer as Tagrisso osimertinib showed a survival benefit in first-line NSCLC. AstraZeneca plc (LSE:AZN; NYSE:AZN) said the oral irreversible inhibitor of EGFR activating mutations significantly improved...
20:20 , Aug 8, 2019 |  BC Innovations  |  Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

Akrevia is harnessing proteases to mask biologics in the periphery and switch them on when they reach the tumor environment to deliver highly immunostimulatory antibodies, cytokines and other immunotherapies that are otherwise toxic to tissues....
22:58 , Aug 6, 2019 |  BC Extra  |  Clinical News

Leap zeroes in on subgroup for DKN-01, Keytruda combo

Shares of Leap tumbled Tuesday as investors digested updated data from the Phase I trial of DKN-01 that showed a lower response than reported in March for the mAb in combination with Keytruda for advanced...
22:35 , Aug 5, 2019 |  BC Extra  |  Clinical News

Bladder cancer data gives Tecentriq another first-line win

With more positive data in first-line bladder cancer, Roche's Tecentriq could become the leading immunotherapy agent for the indication. An interim analysis of the 1,213-patient Phase III IMvigor-130 trial showed Tecentriq atezolizumab plus chemotherapy met...
00:18 , Aug 2, 2019 |  BC Innovations  |  Distillery Therapeutics

SH2B3 as a therapeutic target for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Inhibition of SH2B3 could help treat melanoma. Levels of SH2B3 were higher in tumor samples from 12 patients than in samples of normal skin. In a mouse melanoma cell line,...
00:19 , Jul 31, 2019 |  BC Extra  |  Clinical News

July 30 Clinical Quick Takes: Biogen, Alkermes MS candidate superior to Tecfidera; plus Amgen, Lilly and more

Biogen, Alkermes Phase III MS candidate beats Tecfidera  Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) said diroximel fumarate (BIIB098) met the primary endpoint in the Phase III EVOLVE-MS-2 trial: superiority to Biogen’s Tecfidera dimethyl fumarate...
18:49 , Jul 29, 2019 |  BC Extra  |  Clinical News

A first for Keytruda in triple-negative breast cancer

Nearly a decade after FDA drafted guidance to spur the development of new treatments for neoadjuvant triple-negative breast cancer, Merck’s Keytruda has shown the first positive results in a Phase III trial using pathological complete...
22:27 , Jul 25, 2019 |  BC Extra  |  Clinical News

BMS’s strong 2Q outshines mixed Opdivo data in 1L NSCLC

Investors shrugged off mixed data for Opdivo in first-line lung cancer as Bristol-Myers climbed $2.17 to $45.40 on Thursday on 2Q19 earnings that beat the Street's expectations. Bristol-Myers Squibb Co. (NYSE:BMY) reported postmarket data Wednesday...
15:42 , Jul 25, 2019 |  BC Innovations  |  Distillery Therapeutics

A tumor-targeted Bavencio conjugate with enhanced antitumor efficacy

DISEASE CATEGORY: Cancer INDICATION: Melanoma Coupling a pegylated α-MSH analog to anti-PD-1 antibodies could enhance antitumor immunity. α-MSH is the ligand for MC1R, a receptor upregulated in melanoma cells. Conjugating the α-MSH analog to the...
22:17 , Jul 24, 2019 |  BC Innovations  |  Translation in Brief

Unraveling checkpoint responses in PD-L1-negative cancers

A new study from City of Hope offers a long-sought explanation for why some patients lacking PD-L1 expression on their tumors respond to antibodies against the target, and uncovers a way to boost NK cell...